S2BL99.

Methods	Multicentre, randomised, double‐blind, double‐dummy, parallel‐group. Single dose to treat each of up to 3 attacks. Assessments at 30, 60, and 120 minutes after dosing Second dose of study medication available to treat headache recurrence between 2 and 24 h (second dose could not be taken if the first dose was not effective Rescue medication available after 2 h if response to initial treatment was inadequate
Participants	Aged 18 to 65, at least 1‐year history of migraine (diagnostic criteria equivalent to IHS 1988) with or without aura, and a frequency of 1 to 6 attacks (untreated severity moderate or severe) per month in the past 12 months No treatment with monoamine oxidase inhibitors or serotonin reuptake inhibitors during the course of the study N = 255 M 52, F 203 (80%) Mean age 43 years Proportion with/without aura not reported
Interventions	Sumatriptan 6 mg, n = 125 (122 with moderate or severe baseline pain intensity for attack 1) Oral effervescent acetylsalicylic acid (ASA) 1000 mg + metoclopramide (MCP) 10 mg, n = 130 (125 with moderate or severe baseline pain intensity for attack 1)
Outcomes	Headache relief (at 1 and 2 h) Pain‐free (at 1 and 2 h) Improvement in nausea and vomiting (at 1 and 2 h) Use of rescue medication Adverse events Withdrawals
Notes	Oxford Quality Score: R1, DB2, W1. Total = 4.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐dummy
Study size	Unclear risk	Treatment groups 50 to 200 participants